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Abstract 
We describe, for the first time, stimuli-responsive hydrogel-forming microneedle (MN) arrays 
that enable delivery of a clinically-relevant model drug (ibuprofen) upon application of light. 
MN arrays where prepared using a polymer prepared from 2-hydroxyethyl methacrylate 
(HEMA) and ethylene glycol dimethacrylate (EGDMA) by micromolding. The obtained MN 
arrays showed good mechanical properties. The system was loaded with up to 5% (w/w) 
ibuprofen included in a light-responsive 3,5-dimethoxybenzoin conjugate. Raman 
spectroscopy confirmed the presence of the conjugate inside the polymeric MN matrix. In vitro, 
this system was able to deliver up to three doses of 50 mg of ibuprofen upon application of an 
optical trigger over a prolonged period of time (up to 160 hours). This makes the system 
appealing as a controlled release system for prolonged periods of time. We believe that this 
technology has potential for use in “on-demand” delivery of a wide range of drugs in a variety 
of applications relevant to enhanced patient care. 
 
Keywords: Microneedle, hydrogel, stimuli-responsive, light-triggered 
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Introduction 
 
Microneedle arrays (MN) are minimally-invasive devices that painlessly, and without drawing 
blood, penetrate the skin’s stratum corneum barrier (1-8). MN have been extensively 
investigated in recent years for enhanced transdermal and intradermal delivery of vaccines and 
drug substances (1, 9-14). MN have generally been employed for delivery of bolus doses in 
relatively short periods of times, in contrast to conventional transdermal patches, which are 
used for sustained drug delivery, often over several days. Nevertheless we have recently 
described hydrogel-forming MN that rapidly imbibe skin interstitial fluid upon insertion to 
form discrete in situ hydrogel bulbs, which then control drug administration. In this case, 
release from the swollen MN is determined by the crosslink density of the swollen hydrogel 
network formed and delivery over several days is possible (15-20). In other work, MN have 
been combined with iontophoresis (the application of a small electric current, typically ≤ 0.5 
mA / cm2, to drive ionic and polar molecules across the skin) to facilitate enhanced rates of 
drug delivery across skin pre-punctured with MN (21-25). Most studies involve pre-treating 
skin with MN puncture and then application of an iontophoretic patch, which is not particularly 
convenient. However, iontophoresis set-ups (electrodes, power source, controller) are typically 
complex, expensive and quite bulky. Accordingly, very few iontophoretic patches are on the 
market currently (13), with those that are being very much niche products. As a result, it is 
difficult to imagine even more complex MN-iontophoresis combination products being a 
priority for development by industry. If “on-demand” or pulsatile delivery from a MN system 
is to be developed into a patient-friendly, low cost product, an external stimulus for drug 
delivery from an otherwise benign delivery system would be very useful. In order to address 
the lack of “on demand” transdermal delivery systems some research groups are starting to 
develop MN-based stimulus responsive delivery systems (26-28). 
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In combination with our previous works dealing developing hydrogel-forming MN arrays we 
have previously developed materials impregnated with light-responsive drug conjugates (29, 
30). Such conjugates are able to latently retain drug until light is applied, and the dose of drug 
liberated can be precisely controlled by the total energy applied, in line with the kinetics of 
photolysis of the conjugate. Therefore in this study, we investigated the combination of these 
two technologies to develop hydrogel-based MN arrays containing a light-responsive drug 
conjugate for light-triggered transdermal drug delivery. 
 
Materials and Methods 
 
Chemicals 
Ibuprofen, dichloromethane, dimethylaminopyridine (DMAP), dicyclohexylcarboiimide 
(DCC), acetone, hexane, 2-hydroxyethylmethacrylate, ethylene glycol dimethacrylate, benzyl 
peroxide, phosphate buffer tablets, silica and silica plates were all obtained from Aldrich, 
Gillingham, Dorset, UK. Dichloromethane (DCM), ethanol (EtOH), ethyl acetate (EtOAc), 
hexane, acetonitrile and acetone were all obtained from BDH Laboratories, Poole, Dorset, UK. 
All other chemicals used were of analytical reagent grade. 
 
Synthesis and characterisation of light-responsive ibuprofen conjugates 
2-(3,5-dimethoxyphenyl)-2-hydroxy-1-phenylethanone (3,5-dimethoxybenzoin, 1.00 g, 3.67 
mmol) and ibuprofen (0.76 g, 3.67 mmol) were added to dried dichloromethane (15 ml), to 
which 4-dimethylaminopyridine (DMAP) (0.03g, 0.2mmol) was added. The solution 
temperature was maintained at 0 oC using an ice bath. N,N'-dicyclohexylcarbodiimide (DCC) 
(0.76 g, 3.67 mmol) was added to the solution. The solution was then stirred for 24 hrs at 0 oC, 
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with a drying tube to prevent any water entering the solution. After 24 hrs the dicyclohexylurea 
(DCU) by-product was removed by filtration and the volatiles removed under vacuum. The 
product was purified by flash chromatography on a silica gel column using ethyl acetate:hexane 
(3:2 v/v) as the eluent. The product, a light-responsive ibuprofen conjugate was a viscous 
yellow oil (1.29 g, 73 %, 2.80 mmol). (CDCl3): 7.84-7.87 (Ar-1-2-H9, s, dd, d,  J = 6.25 Hz), 
7.42 ( Ar-1-2 – H11, m ), 7.30-7.34 (Ar-1- H10,  m ), 7.20-7.25 ( Ar-3- H5,  m), 7.14-7.19( Ar-3-
, H3, dd, J = 5.0),  6.75 (H14, d, J = 1.9 Hz), 6.5-6.55 ( Ar- 1-2- H8,  dd,  J = 1.0 Hz),  6.32-6.39 
( Ar-2- H13, m), 4.12-4.18 (H7 –CH, m),  3.71-3.79 (Ar-2- H12 -OCH3 d, J = 1.0 Hz),  2.41-2.48 
(H4 - CH2, m),  1.82-1.87 (H2 – CH, m),  1.48-1.59 (H6 - CH3 , m ),  0.75-0.82 (H1 – CH3, m  J 
= 5.0 Hz). IR max/cm-1 (KBr): 2945 methine group (CH), 1670 ketone group (R-C=O-R), 1730 
ester (R-C=O-OR). m/z(%): 461.2 (M+, 59), 255.3 (434), 920.8 (100), 919.3 (24), 942.9 (12), 
413.4 (9), 212.3 (3), 227.3 (8), 256.3(7). Elemental analysis: C29H32O5 requires: C 75.63%, H 
7%, O 17.37%. Found: C 75.62%, H 7.01%, O 17.35%. 
 
Preparation and physicochemical characterisation of drug loaded MN arrays 
Laser-engineered silicone micromould templates were used in micromoulding of MN arrays 
and were microfabricated using a previously-reported approach (31). The moulds were 
composed of 9 (3x3) or 121 (11x11) needles perpendicular to the base, of conical shape and 
600 μm in height, with base width of 300 μm and interspacing of 300 μm. 2-hydroxyethyl 
methacrylate (HEMA, 98.6% w/w), ethylene glycol dimethacrylate (EGDMA, 1% w/w) and 
BPO (0.4%, w/w) and the light-responsive ibuprofen conjugate (1 to 5% w/w) were mixed with 
a magnetic stirrer until all of initiator was dissolved.  MN arrays were prepared only with the 
HEMA polymer to evaluate the ability of this type of polymer to form MN. For this purpose 
MN moulds were filled to the top with the HEMA, EGDMA and BPO solution (0.5 g), 
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centrifuged at 3000 rpm, refilled to replace part of the evaporated solution and placed in the 
oven at 90 oC for two hours.   
Additionally swelling kinetics of hydrogels obtained by crosslinking HEMA (pHEMA) was 
evaluated. Hydrogels squares (0.81 ± 0.05 g; 12.6 ± 0.4  x 16.6 ± 0.4  x  5.2 ± 0.2 mm) were 
weighed as mo and then swollen in 50 mL of pH 7 phosphate buffer solution (PBS) for 24 h at 
room temperature. At regular intervals, the films were removed, dried with filter paper to 
eliminate excess surface water and weighed as mt (hydrogels). The percentage swelling, was 
calculated, respectively, by using Equation 1. 
 
% Swelling =100 x (mt – mo) / mo        (1) 
 
In order to prepare MN for mechanical testing and drug delivery, the polymer mixture was 
poured into the laser drilled 3x3 or 11x11 silicon moulds at weight of 0.5 g per array, the 
moulds were then centrifuged for 10 minutes to remove any air bubbles at 3000 rpm and then 
placed in the oven at 90 oC for two hours, the MN moulds were removed from the oven, allowed 
to cool and then the MNs were removed from the moulds. The “sidewalls” formed by the 
moulding process were removed using a heated blade, as described previously (31). It is 
important that these moulds remain covered to protect them from light. Uniformity with regards 
to height and width of each batch of MN arrays was examined by a digital microscope under 
the magnification 180x, using the ruler function of the microscope software.  
Raman spectroscopy was carried out using on hydrated 1 cm2 squares of pHEMA and on 
pHEMA incorporated with light responsive conjugate. Raman spectra and maps were obtained 
using an Avalon Instruments Raman Station R3 coupled to an Olympus BX 50 microscope. 
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Samples were placed on a microscope slide and Raman scattered light from a 785nm laser 
operating at 300mW focused on the surface of the sample was collected between 400-3200cm-
1 at a resolution of 2 cm-1, and with a total collection time of 120 s. 
MN characterisation 
Formed MN arrays were visualised using a Keyence VHX-700F Digital Microscope equipped 
with a VH-Z20R lens (Keyence, Osaka, Japan), which allows automatic sizing of multiple MN, 
facilitating quality control in terms of efficiency and reproducibility of MN formation within 
and between individual arrays. Additionally needle dimensions where evaluated using an Aigo 
Digital Viewer GE-5 (Aigo, Beijing, China). MN arrays were also subjected to compression 
tests in order to ascertain their mechanical strength. Mechanical properties were evaluated 
using a TA-XT2 Texture Analyser (Stable Microsystems, Haslemere, UK) in compression 
mode, as described previously [16]. MN arrays were visualised before and after application of 
the compression load using a desktop light microscope (GXMGE-5 digital microscope, 
Laboratory Analysis Ltd., Devon, UK). 
 
In vitro drug delivery studies 
These experiments were performed with a system employing Franz-diffusion cells. pHEMA 
MNs with 1% or 5% loading of the photoresponsive drug conjugate were manufactured as 
detailed in MN preparation methodology. The MNs were then punctured through a synthetic 
skin membrane. At this stage they were visualised under a microscope to check no damage had 
occurred to the MNs and that they had all punctured through the synthetic membrane. The MN 
arrays were then irradiated with a 15W Hg discharge UV lamp source at 365 nm at a fixed 
distance of 10 mm from the light source for 1 hr. At the 1 hr time point they were then attached 
to the receptor compartment of the Franz-diffusion cells, and the receptor phase volume was 
9 
 
recorded. The surface area of the MN array exposed to the receptor compartment was 2.96 cm2. 
The receptor medium was PBS. A measured volume of receptor solution (3 ml) was added to 
each receptor compartment with a magnetic stirring bead. The diffusion cells were placed on a 
magnetic stirring plate in a water bath kept at 36 ºC, resulting in skin temperature at the 
membrane surface of approximately 32 ºC during the experiment. Using a needle, samples (3 
ml) were collected from the receptor compartment at defined time intervals and were 
immediately refilled by fresh receptor solution. These samples were then assayed by UV 
spectroscopy at a wavelength of 365 nm. The experiment included 3 replicates of pHEMA 
arrays (3x3 and 11x11 MN arrays) loaded with the photoresponsive drug conjugate and 3 
replicates of pHEMA arrays without any photoresponsive drug conjugate as the experimental 
control. Repeated sampling occurred over a 24 hr time frame, with repeated 1hour irradiations. 
 
Statistical analysis 
Where appropriate, data was analyzed using a one-way ANOVA with post-hoc comparisons 
performed using the Tukey-Kramer test. In all cases, p < 0.05 denoted significance. Statistical 
Package for the Social Sciences, SPSS 18.0 version 2.0 (SPSS, Inc., Chicago, IL, USA), was 
used for all analyses. 
 
Results 
The light-responsive ibuprofen conjugate was prepared by the Steglich esterification of the 
carboxylic acid of ibuprofen and the alcohol of 3,5-dimethoxybenzoin in dichloromethane in 
the presence of DCC and DMAP (Figure 1A); silica column chromatography afforded the 
analytically pure conjugate (as determined by NMR, infrared spectroscopy and mass 
spectrometry) in 73 % yield. Figure 1B shows also the scheme of light triggered release of 
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ibuprofen when the conjugate is irradiated under certain type of light yielding the free drug and 
2-phenyl-5,7-dimethoxybenzofuran (29, 30, 32). 
 
Figure 1. Synthesis of light-responsive ibuprofen conjugate (A). Light-triggered release of 
ibuprofen from the conjugate (B). 
 
The manufacture of novel pHEMA MNs with varying percentages of EGDMA (1% to 5%), 
yet higher EGDMA loadings yielded mechanically unstable gels. We found that the pHEMA 
MNs with the 1% EGDMA composition were more uniform with regards to height and width, 
and displayed more reproducibility than batches of MN arrays with 5% EGDMA, therefore we 
focused on pHEMA MN arrays incorporating 1% EGDMA (see supporting information Figure 
S1). MN arrays prepared using the selected polymer were evaluated using microscopy (Figure 
2). All the needles were properly formed and the 3D reconstruction of the surface of some 
needles in an 11x11 arrays showed that the needle heights of around 450 µm. 
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Additionally, the swelling kinetic of the selected pHEMA hydrogel was evaluated (Figure 3). 
As it can be seen the water uptake is continuous during the first hours reaching a 35% of 
swelling after 24 hours. 
 
 
Figure 2. Microscopy images of PHEMA MNs  containing 1% EGDMA prepared using 3x3 
(A) and 11x11 (B) moulds. 3D reconstruction of 6 needles from 11x11 pHEMA MN array (C). 
The 3D pictures without colour scale can be found on the Supplementary Information Figure 
S2. 
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Figure 3. Swelling curve for pHEMA hydrogel containing 1% of EGDMA in PBS. Data are 
shown as mean ± standard deviation of 3 replicates. 
 
In order to ascertain the presence of the light responsive conjugate in the pHEMA network, 
Raman spectroscopy was used. The spectrum of pHEMA with 1% of the light responsive 
conjugate incorporated into the matrix (Figure 4) showed peaks at 990 cm-1, 992 cm-1, 1596 
cm-1 and 1622 cm-1 that confirm the presence of the light responsive conjugate. The 990 cm-1 
and 992 cm-1 peaks are attributed to the presence of the ester bond (C-O-C) and the peaks at 
1596 cm-1 and 1622 cm-1 are due to the aromatic groups which are present in the conjugate 
(33). 
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Figure 4. Raman spectra of pHEMA and pHEMA with 1% of the light responsive conjugate 
incorporated into the matrix. 
 
Mechanical properties of the materials containing the light responsible conjugate were 
evaluated. We observed that the presence of the light responsive conjugate within the hydrogels 
resulted in slight modifications to the bulk mechanical properties of the gels when exposed to 
tensile stress (see supporting information Table S1), however ANOVA showed these different 
results to be statistically insignificant. Furthermore, the heights and widths distribution of the 
MNs seem to be independent of the photoresponsive conjugate concentration (Table 1). 
Furthermore, it is noticeable that the obtained needles were shorter than expected (ca. 425 µm 
instead of 600 µm). This behaviour has not been obtained in our group before in the production 
of Gantrez® hydrogel-forming MN arrays (16, 19). Nevertheless the manufacturing process 
was totally different and in this case it can be due to the different crosslinking process. 
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Table 1. Morphology of microneedles prepared from pHEMA formulations containing 
increasing loadings of light responsive conjugate. Data are shown as means ± standard 
deviation of eight replicates. 
MN arrays Height (µm) Width at base (µm) 
1% light responsive 
conjugate 
424.12 + 1.04 313.25 + 1.5 
5% light responsive 
conjugate 
425.03 +  2.2 315.00 + 1.9 
 
If used as transdermal drug delivery patches, the mechanical properties of the MN arrays under 
compression are of greater importance, consequently, the strength of the different MN 
formulations was determined by calculating the force required to fracture the microneedles 
(Figure 5). Three different hydrogel formulations (pHEMA, pHEMA with 1% light responsive 
conjugate, and pHEMA with 5% light responsive conjugate) were studied with a range of 
applied forces (0.05 N to 0.5 N per needle). Exposure of the hydrogel-based MN to 
compression results in their deformation, yet there was no significant difference in the degree 
of deformation between the three formulations. Indeed, exposure to the minimal applied force 
(0.05 N per needle) resulted in approximately 2% average reduction in the height, whereas 
under the maximum load (0.5 N per needle), MN height was reduced by approximately 8.3%. 
The significance of the compression experiments can only be properly evaluated when 
compared with the corresponding insertion forces (34). Recently, Larrañeta et al. showed that 
the maximum average force that a group of human volunteers exerts when applying MNs was 
32 N (35). In another research work, Lutton et al. reported that when inserting other type of 
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hydrogel-forming MN arrays (32x32 needles; 600 µm of needle length) in a skin simulant using 
this force (0.16 N/needle) the needle height reduction was ca. 3% (36). These values are 
consistent with those obtained in this work. 
 
 
Figure 5. Images of different MN arrays after 0N, 0.05N, 0.1N, 0.3N and 0.5N have been 
applied (force per needle). A graph depicting the average % reduction in height of three 
different type of pHEMA microneedle array formulations (pHEMA, pHEMA loaded with 1% 
conjugate 1 and pHEMA loaded with 5%) as different forces ranging from 0.05N to 0.5N are 
applied to the microneedle arrays. Data are shown as mean ± standard deviation of five 
replicates. 
 
To demonstrate the ability of these hydrogel-based MNs to deliver a clinically relevant model 
therapeutic agent (ibuprofen) in vitro, two different MN array designs (3x3 and 11x11 arrays), 
and two different loadings of the light responsive conjugate (1% and 5%) were studied. The 
drug release profiles of a 3x3 MN arrays loaded with the light responsive conjugate after 
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successive periods of 1 hour of irradiation (Figure 6A) show that the majority of drug is 
released after the first two periods of irradiation, with a significant reduction of ibuprofen 
release after the third irradiation. Ibuprofen release from 3x3 MN arrays triggered by 3 cycles 
of exposure to light for 1 hour followed by 5 hours of rest (Figure 6B) logically shows that 
hydrogels with higher loadings of the conjugate contained slightly more residual conjugate 
after the same duration of irradiation, suggesting their suitability for applications requiring 
prolonged exposure to a specific drug. Similar trends in ibuprofen release profiles were 
obtained from the 11x11 MN arrays (Figure 6C). The cumulative fraction of ibuprofen 
released from 3x3 and 11x11 arrays after successive periods of 1 hour exposure to light without 
a rest period (Figure 6D), show that drug release from the 11x11 arrays are greater than from 
3x3 arrays, because the surface areas of the 11x11 arrays are greater, thereby enabling faster 
diffusion of the drug from the surface of the microneedle arrays. 
 
 
Figure 6. Cumulative fractional release profiles of ibuprofen from 3x3 MN array loaded with 
the light responsive conjugate, after successive periods of irradiations at 365nm for 1 hour (A). 
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Data are shown as mean ± standard deviation of six replicates. Ibuprofen release from 3x3 MN 
array with release triggered by 3 cycles of exposure to light for 1 hour (B). Ibuprofen release 
from 11x11 MN array with release triggered by 3 cycles of exposure to light for 1 hour (C). 
Total cumulative fraction of ibuprofen released from 3x3 and 11x11 arrays after successive 
periods of exposure to light (D). Data are shown as mean ± standard deviation of six replicates. 
 
Discussion 
The capability to control the quantity, location and time of drug dosing is one of the main 
objectives in the design of drug delivery systems (37). For these purposes systems responsive 
to different stimulus, such as temperature, pH or light among others have been prepared (38-
41). A light triggered MN drug delivery system have been designed and successfully tested in 
vitro for the release of a clinical relevant model drug: ibuprofen. This systems combines the 
advantages of MN transdermal delivery systems with a light-controlled drug liberation reaction 
allowing a high level of control for the dose, the timing of the release process, and its location. 
Ibuprofen was selected as a model drug for this study. It was conjugated with 3,5-
dimethoxybenzoin to form a light responsible compound. This type of conjugate has been 
previously synthetized and tested using different model molecules such as acetyl salicylic acid, 
ibuprofen, and ketoprofen (29). When irradiated with light of specific wavelength the conjugate 
is broken yielding the free drug and 2-phenyl-5,7-dimethoxybenzofuran (Figure 1B) (29, 30, 
32). The ibuprofen conjugate was successfully loaded in pHEMA hydrogels crosslinked using 
EGDMA. Nevertheless, prior to the incorporation of the conjugate inside the hydrogel matrix 
the optimal composition of HEMA and EGDMA for MN preparation was selected. The results 
suggested that the use of a lower amount of EGDMA (1%) leads to the formation of more 
homogenous distribution of needle length in the array (see supporting information Figure S1). 
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Therefore this composition was selected over the one containing 5% of EGDMA. Additionally 
the swelling kinetics of this type of hydrogel was evaluated (Figure 3). The swelling process 
of this type of material requires more than 24 hours to reach maximum swelling. The swelling 
process for this type of material is slower in comparison to other materials used for the 
preparation of hydrogel-forming MN arrays such as Gantrez® AN-139 or Gantrez® S-97 that 
are able to reach maximum swelling degrees in less than 24 hours (20, 42). Moreover, the 
maximum amount of water that pHEMA hydrogels are able to uptake is substantially smaller 
than the previously described materials. The pHEMA hydrogel shows maximum swelling 
degrees of around 50% while for Gantrez® hydrogels the values are higher than 1000% after 
24h (20, 42).  The lower swelling degree combined with the slower swelling process makes 
this type of material more suitable for the production of prolonged drug delivery systems. 
Besides, the crosslinking time required to prepare pHEMA MN arrays is shorter than for 
Gantrez® ones (2 h at 90°C vs. 24 h at 80°C). This process can be accelerated by using 
alternative heating sources such as microwave radiation (42). The optimization of the 
crosslinking time will be mandatory for the development of an industrial manufacturing 
process. 
The next step was the incorporation of the ibuprofen conjugate in the pHEMA hydrogel 
matrices. The conjugate was incorporated in the solution containing HEMA monomer, 
EGDMA and the initiator. After the polymerization reaction, the presence of the conjugate was 
confirmed using Raman spectroscopy (Figure 4). The conjugate was attached to the polymer 
matrix through non-covalent interactions and consequently immobilized until the covalent ester 
that bound ibuprofen with the 3,5-dimethoxybenzoin was broken (43). The incorporation of 
the conjugate has no statistical significant effect on the mechanical properties of the MN arrays 
(Figure 5).  
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Finally, MN arrays loaded with the light responsible conjugate were tested in vitro for 
transdermal light-triggered delivery of ibuprofen. The experiment was carried out using Franz 
Cells and Silescol® membrane as skin simulant. The reason for the use of the Silescol 
membrane was that the experiment takes several days to be complete and the integrity of 
excised skin during this time will be compromised. As can be seen in Figure 5, the irradiation 
of the MN arrays with 365nm light triggers the release of ibuprofen. This process can be 
repeated at least three times in a consecutive way. The amount of ibuprofen released can be 
tailored by modifying the number of needles in the array, and the concentration of the drug in 
the polymeric matrix. Additionally the system allows the release of ibuprofen during prolonged 
periods of time (up to 160 h). Additionally it is important to note that despite of the fact that 
the conjugate is not covalently bound to the polymer matrix there is no significant release from 
pHEMA matrices of the other major product obtained after irradiation of the conjugate (2-
phenyl-5,7-dimethoxybenzofuran) (Figure 1B) due mainly to its hydrophobicity (32). 
Nevertheless, in future studies this fact should be evaluated deeply in order to ascertain the 
safety of the device. 
It is important to notice that UV radiation is shown to be the major etiologic agent in the 
development of skin cancers (44). Therefore this system cannot be used directly into patients 
in the way it is described here. The work presented here is a probe of concept and a modified 
version of the system should be used. Based on our previous research on hydrogel forming MN 
arrays we propose a hydrogel-forming MN array system (16, 20) containing a backing layer 
made with the material described in this work. Between the MN array and the backing layer a 
porous layer of a material that blocks UV radiation should be included. Therefore radiation can 
be applied to the system without reaching the skin surface. 
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Triggerable systems such as the system presented here facilitate multiple drug dosages with a 
single administration. This type of delivery system is of great interest especially for the 
treatment of pain (45). A good example of this situation are cancer patients that often suffer 
from various levels of pain as symptom of the cancer or as side effect of the cancer treatment. 
To the date only a few authors have dealt with the combination of MN arrays and stimuli-
responsive systems (26-28). Huang et al. developed a biochip for real-time measurement of 
glucose concentration and automatic insulin injection (28). This system was based on electronic 
systems rather than in stimuli-responsible materials. Recently, Chen et al. developed a MN 
system loaded with silica-coated lanthanum hexaboride nanoparticles that are capable to 
release a model molecule (Rhodamine 6G) on demand when the array was irradiated with near 
infrared radiation (26). The MN array was made of polycaprolactone. When the system was 
irradiated with infrared radiation, the presence of light-sensitive nanostructures caused a 
temperature increase of the array. This temperature increase leads to microneedle melting and 
enabling drug release. After 132 minutes and multiple infrared stimulated release cycles the 
system was able to release up to 80% of its cargo. The system described in the present paper 
was able to release ibuprofen during longer periods of time (Figure 6) making our system more 
appealing for long term drug administration. 
 
Conclusion 
A light-responsive MN drug delivery system has been designed and successfully tested in vitro 
for the release of a model drug, ibuprofen. The coupling of the application of light to the release 
of a predictable dose of drug has been demonstrated. The selected polymer for MN fabrication, 
pHEMA crosslinked with EGDMA, presented good mechanical properties and could be used 
to form MN arrays successfully using a micromolding technique. This technology has 
considerable potential for use in situations where “on-demand” drug delivery is required, with 
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patient- or physician-controlled analgesia an obvious example. Our next steps will be in vivo 
studies aimed at ascertaining the efficacy of the system in a suitable animal model. Due to the 
potentially harmful effect of UV radiation on the skin, the system will be modified before its 
application in vivo, perhaps by including the drug and light-sensitive conjugate in the baseplate 
and having the needles protrude through an opaque barrier membrane into the skin. Moreover, 
as we take the technology forwards, we will also consider optimization of the crosslinking time 
using microwave radiation and the minimising the potential for release of any free 2-phenyl-
5,7-dimethoxybenzofuran from the array into skin following irradiation. 
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Supporting Information 
 
Figure S1. Morphology of microneedles prepared from the different PHEMA formulations: 
1% EGDMA, height 425.07 ± 2.82 μm and width 313.25 ± 1.23 μm (A); 5%  EGDMA, height 
425.00 ± 12.34 μm and width 323.00 ± 14.53 μm (B). Data are shown as means ± standard 
deviation of eight replicates. 
 
 
Figure S2. 3D reconstruction of 6 needles from 11x11 pHEMA MN array 
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Table S1. Influence of the incorporation of the light responsive conjugate on the bulk 
mechanical properties of the hydrogels. 
Sample UTS (MPa) Young’s Modulus 
(GPa)    
% Elongation at 
break 
pHEMA 0.40 + 0.09 0.72 + 0.06 154.0 + 16.8 
pHEMA 1% light 
responsive conjugate 
0.37 + 0.13 1.13 + 0.21 155.5 + 8.9 
pHEMA 5% light 
responsive conjugate 
0.32 + 0.10 1.42 + 0.08 162.5 + 7.3 
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